Emyria has today announced the appointment of global pharmaceutical expert, Dr Karen Smith, as chair of its Strategic Advisory Board. Dr Smith’s appointment boosts Emyria’s global clinical trial and regulatory approval expertise to accelerate drug registration initiatives.

Dr Smith has overseen more than 100 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including neuroscience, rare disease, oncology, cardiology, dermatology, oncology and anti-infective.

She has also held key chief executive officer and chief medical officer roles at some of the most innovative biotech and pharmaceutical development companies in the world including holding the role of CMO and head of R&D at Jazz Pharmaceuticals, which recently acquired GW Pharma for $7.2 billion.

Read the ASX announcement here